Company profile for Inovio Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Inovio's technology platform is capable of activating antigen-specific immune responses. Aptly named ASPIRE™ (Antigen SPecific Immune REsponses), this unique technology is primed to change the way cancer and infectious disease are treated. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states...
Inovio's technology platform is capable of activating antigen-specific immune responses. Aptly named ASPIRE™ (Antigen SPecific Immune REsponses), this unique technology is primed to change the way cancer and infectious disease are treated. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—ASPIRE is realizing the true promise of immunotherapy.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
660 W. Germantown Pike, Suite 110 Plymouth Meeting, PA 19462
Telephone
Telephone
267-440-4200
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/inovio-to-participate-in-december-investor-conferences-302618252.html

PR NEWSWIRE
18 Nov 2025

https://www.prnewswire.com/news-releases/inovio-announces-proposed-public-offering-302610778.html

PR NEWSWIRE
11 Nov 2025

https://www.prnewswire.com/news-releases/inovio-announces-pricing-of-25-million-public-offering-302611604.html

PR NEWSWIRE
11 Nov 2025

https://www.prnewswire.com/news-releases/inovio-reports-third-quarter-2025-financial-results-and-recent-business-highlights-302610540.html

PR NEWSWIRE BIO
10 Nov 2025

https://www.prnewswire.com/news-releases/inovio-completes-rolling-bla-submission-seeking-accelerated-approval-for-ino-3107-as-a-treatment-for-rrp-in-adults-302602227.html

PR NEWSWIRE
03 Nov 2025

https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302601463.html

PR NEWSWIRE
31 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty